The Filing Desk

Atara Biotherapeutics

ATRA · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

ATRA · Last close · November 19, 2026
$6.34
Value Atara Biotherapeutics yourself

Atara Biotherapeutics' revenue fell 6.3% to $121 million in fiscal 2025. Its operating margin was 29.7%, up from −64.7% a year earlier. Free cash flow was −$51 million. The diluted share count rose 69.8%.

Atara Biotherapeutics, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 16, 2026 · 0001193125-26-108361 Updated
Revenue
$121M
6.3%
Operating margin
29.7%
94.4 pts
Net income
$33M
 
Free cash flow
−$51M
 
Return on equity
—
 
Market cap
$97M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (1-for-25), so every year is on today's share basis.

Charts show fiscal years, from the 10-K filings.

What Atara Biotherapeutics does

Atara Biotherapeutics develops cell therapies made from donated immune cells called T cells. Its one approved product, Ebvallo (tab-cel), treats a rare and aggressive cancer, EBV+ PTLD, that can follow an organ or stem cell transplant when the Epstein-Barr virus gets out of control in patients with weakened immune systems. Because the cells come from donors and are made ahead of time, a dose can be taken from stock rather than built from each patient's own cells. Ebvallo is approved in the European Economic Area, the UK and Switzerland, but not in the U.S.

Atara does not sell Ebvallo itself. A French drugmaker, Pierre Fabre, holds the worldwide rights and now handles the medicine's manufacturing, trials and dealings with regulators at its own cost. Atara earns milestone payments and royalties on sales, and has sold part of its European royalties to an investor, HCRx. Atara is eligible for up to $556.0 million in further milestone payments outside the original European territory, if certain goals are met.

The U.S. Food and Drug Administration turned down the application to sell tab-cel twice: in January 2025 over a manufacturing site, and in January 2026 because it no longer accepted the main trial as adequate evidence. In 2025 Atara stopped its other programs, cut its staff to about 15 employees, and began looking at options such as a merger or a sale of assets.

Its biggest risks, as it describes them

  • Its business depends almost entirely on one product, tab-cel, which the FDA has turned down twice in the U.S.
  • It relies on Pierre Fabre to make, test, win approval for and sell tab-cel, and Pierre Fabre could fall short.
  • It has lost money since it began and needs new financing soon, which could force it to wind down.
  • Its search for a merger, sale or other deal may not succeed or may not deliver the benefits it hopes for.
  • Manufacturing donor-cell therapies is complex, and problems at partners' plants could cut supply.
From Atara Biotherapeutics's annual report on Form 10-K, filed March 16, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow
Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments37124352428
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage−10,639.4x−752.0x−52.2x−18.1x9.5x
Current ratio3.6x3.7x0.7x0.5x0.8x
Quick ratio3.6x3.7x0.7x0.4x0.8x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Atara Biotherapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $5.7 million of Atara Biotherapeutics shares on the open market, and 4 insiders sold $3.8 million.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 16, 2026AnhCo NguyenPresident and CEO, DirectorSold6,094$6.46$39,368Form 4
Sep 4, 2026Brian N CherryDirectorBought104,166$9.60$999,994Form 4
Aug 17, 2026AnhCo NguyenPresident and CEO, DirectorSold5,062$8.08$40,901Form 4
May 18, 2026AnhCo NguyenPresident and CEO, DirectorSold5,241$9.13$47,850Form 4
May 18, 2026Yanina Grant-HuertaChief Accounting OfficerSold2,414$9.13$22,040Form 4
May 7, 2026EcoR1 Capital LLC10% ownerBought507,407$9.35$4.7 millionForm 4
May 7, 2026Panacea Innovation Ltd10% ownerSold313,446$10.10$3.2 millionForm 4
Mar 2, 2026AnhCo NguyenPresident and CEO, DirectorSold2,996$5.09$15,247Form 4
Mar 2, 2026Yanina Grant-HuertaChief Accounting OfficerSold2,104$5.08$10,688Form 4
Jan 12, 2026James HuangDirector, 10% ownerSold80,554$6.07$488,963Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−2,351.8%1,350.5%−48.5%
Altman Z''−51.20−71.22−315.39
Accruals ratio−30.7%−12.2%129.3%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailPass
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassFail
Debt fell relative to assets———
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Atara Biotherapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Atara BiotherapeuticsFY25−6.3%29.7%−42.2%———
Monte Rosa TherapeuticsFY2563.5%−43.8%−22.2%———Compare
XencorFY2513.7%−141.3%−110.1%−19.9%—3Compare
AgenusFY2510.4%−17.7%−67.6%——3Compare
ImmunityBioFY25668.3%−226.0%−272.6%——3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue——————649129121
Revenue growth———————−86.5%1,404.0%−6.3%
Gross profit——————————
Research and development568116821624528227222515237
Operating income−81−122−237−296−309−340−280−276−8336
Net income−79−120−231−291−307−340−228−276−8533
Diluted EPS (US$)−68.75−100.00−131.75−141.75−103.75−90.75−56.00−65.19−11.412.57
Diluted shares (millions)11223444813
Cash flow
Cash from operations−60−88−180−236−181−220−270−193−69−51
Capital expenditure3203664114100
Free cash flow−63−108−216−241−185−231−275−194−69−51
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation17233452515454452710
Balance sheet at fiscal year end
Cash and short-term investments25616631025950137124352428
Debt incl. finance leases——————————
Total assets26421839234358846837616610920
Total liabilities1040535212618825026520659
Shareholders' equity25417833929146228012799−97−38
Margins and ratios
Gross margin——————————
Operating margin——————−441.2%−3,219.5%−64.7%29.7%
Net margin——————−359.1%−3,220.9%−66.2%27.1%
Free cash flow margin——————−432.0%−2,265.2%−53.5%−42.2%
Rule of 40 (growth + FCF margin)———————−2,351.8%1,350.5%−48.5%
Return on capital——————————
Return on equity−27.8%−55.4%−89.2%−92.4%−81.4%−91.7%−112.4%−244.5%——
Return on assets−26.9%−49.6%−75.7%−79.2%−65.9%−64.4%−54.1%−101.9%−62.2%50.5%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Atara Biotherapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Atara Biotherapeutics.